IonOpticks and Biognosys Announce Strategic Partnership
IonOpticks, recognized globally as a provider of innovative chromatography solutions, has formed a significant alliance with Biognosys, an esteemed entity in mass spectrometry-based proteomics research. This collaboration aims to advance the field of proteomics by creating specialized chromatography columns that will become standard in Biognosys’ research services.
Custom Solutions for Enhanced Proteomic Research
IonOpticks has meticulously designed custom chromatography columns to meet the distinct requirements of Biognosys. This column will serve as a crucial component in facilitating deeper and reproducible proteome profiling essential for modern research. These tools are tailored specifically for use in Biognosys' flagship contract research service platforms known as TrueDiscovery, TrueSignature, and TrueTarget.
Benefits of Tailored Chromatography
With a focus on quality, the joint effort ensures that the chromatography columns align seamlessly with Biognosys' workflows. This alignment maximizes sensitivity, depth of coverage, and reproducibility—key factors that significantly impact research outcomes and the overall success of LC-MS workflows. Such advancements foster better discovery processes within biotech and pharmaceutical research.
Leaders in the Industry
Xavier Perronnet, CEO of IonOpticks, expressed enthusiasm about collaborating with Biognosys, highlighting that this partnership embodies their mutual commitment to excellence in proteomics. The custom column’s performance aligns with IonOpticks’ goal of providing superior chromatography solutions tailored for expansive market needs.
Expert Insights from Biognosys
Dr. Lukas Reiter, Chief Technology Officer at Biognosys, shared his perspective, emphasizing the significance of chromatographic efficacy in LC-MS workflows. He noted the importance of collaboration with IonOpticks to innovate a column designed specifically for their pressing research requirements, achieving their high performance standards.
Aiming for Innovation in Proteomics
Both companies are excited to push the boundaries of proteomics research through this partnership, aiming to provide high-performance solutions that inspire innovation and efficiency in the field. This collaboration not only addresses current scientific needs but also sets the foundation for future developments in proteomics.
Commitment to Research Excellence
IonOpticks is committed to enhancing mass spectrometry performance, which is crucial for critical applications like drug discovery and phosphoproteomics. Their custom solutions are aimed at helping the global research community extract more profound insights from biological samples.
About IonOpticks
IonOpticks specializes in creating high-performance chromatography solutions that significantly enhance mass spectrometry and proteomics research. By improving sensitivity in mass spectrometry sample analysis, their innovation empowers scientists and clinicians to derive deeper insights from various biological samples. This capability is particularly valuable across a wide range of biomedical and health research applications.
About Biognosys
At Biognosys, innovation drives their efforts to revolutionize proteomics with their advanced research service platforms. Their portfolio includes cutting-edge tools like the flagship software, Spectronaut, and the PQ500™ kit, enabling actionable insights in research, drug development, and clinical decision-making. With renowned precision, their technologies facilitate the quantification of thousands of proteins, making proteomics accessible on a global scale.
Frequently Asked Questions
What is the purpose of the partnership between IonOpticks and Biognosys?
The partnership aims to produce custom chromatography columns that enhance the capabilities of Biognosys’ proteomics research services.
What benefits do the custom chromatography columns offer?
These columns are designed to maximize sensitivity, depth of coverage, and reproducibility, essential for effective LC-MS workflows.
Who are the key executives involved in this collaboration?
Xavier Perronnet, CEO of IonOpticks, and Lukas Reiter, CTO of Biognosys, are leading this initiative.
How will this collaboration impact proteomics research?
This collaboration is expected to set new benchmarks in proteomics, leading to more innovative and efficient research methodologies.
What is the mission of IonOpticks?
IonOpticks is dedicated to delivering high-quality chromatography solutions that support the expanding needs of the research community.
